Coherus Oncology (CHRS) Gross Margin (2019 - 2026)
Coherus Oncology (CHRS) reported Gross Margin of 69.02% for Q1 2026, up 393.0% on a YoY basis from 14.0% in Q1 2025, and up 1.09% sequentially from 68.27% in Q4 2025.
Coherus Oncology (CHRS) Gross Margin (2019 - 2026) Analysis & Trends
Coherus Oncology (CHRS) has 8 years of Gross Margin data on file, last reported at 69.02% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 393.0% year-over-year to 69.02%; the trailing twelve-month figure through Mar 2026 stood at 68.06% (down 56.0% YoY), and the FY2025 full-year result was 67.24%, up 31.0% from the prior year.
- Gross Margin climbed to 69.02% in Q1 2026, from 68.27% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 84.41% in Q1 2022 to a low of 7.6% in Q4 2023.
- A 5-year average of 58.98% and a median of 65.09% in 2025 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin tumbled 6108 bps in 2023 and jumped 5684 bps in 2024, its largest moves.
- Tracing CHRS's Gross Margin over 5 years: stood at 68.68% in 2022, then sank by 89 bps to 7.6% in 2023, then jumped by 748 bps to 64.44% in 2024, then climbed by 6 bps to 68.27% in 2025, then climbed by 1 bps to 69.02% in 2026.
- Business Quant data shows CHRS's Gross Margin at 69.02% in Q1 2026, 68.27% in Q4 2025, and 67.84% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | 69.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.02% |
| Dec 31, 2025 | 68.27% |
| Sep 30, 2025 | 67.84% |
| Jun 30, 2025 | 66.89% |
| Mar 31, 2025 | 65.09% |
| Dec 31, 2024 | 64.44% |
| Sep 30, 2024 | 54.91% |
| Jun 30, 2024 | 82.43% |
| Mar 31, 2024 | 37.65% |
| Dec 31, 2023 | 7.60% |
| Sep 30, 2023 | 56.14% |
| Jun 30, 2023 | 57.68% |
| Mar 31, 2023 | 47.98% |
| Dec 31, 2022 | 68.68% |
| Sep 30, 2022 | 22.43% |
| Jun 30, 2022 | 81.25% |
| Mar 31, 2022 | 84.41% |
| Dec 31, 2021 | 83.50% |
| Sep 30, 2021 | 74.21% |
| Jun 30, 2021 | 80.95% |